Eagle Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Eagle Pharmaceuticals has a total shareholder equity of $252.0M and total debt of $70.2M, which brings its debt-to-equity ratio to 27.8%. Its total assets and total liabilities are $404.8M and $152.8M respectively. Eagle Pharmaceuticals's EBIT is $41.7M making its interest coverage ratio 7.2. It has cash and short-term investments of $15.4M.
Key information
27.8%
Debt to equity ratio
US$70.19m
Debt
| Interest coverage ratio | 7.2x |
| Cash | US$15.35m |
| Equity | US$252.04m |
| Total liabilities | US$152.78m |
| Total assets | US$404.82m |
Recent financial health updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21
Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Recent updates
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
Sep 21Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
Jul 13Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly
Jun 21These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Oct 27Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia
Oct 12Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Sep 27Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Aug 18Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be
Aug 15Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M
Aug 09These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely
Jul 06Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price
Apr 29Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt?
Dec 16Shareholders May Be Wary Of Increasing Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Compensation Package
Jul 06Eagle Pharmaceuticals: A Potential Reopening Play
Jun 16Eagle Pharmaceuticals EPS misses by $0.49, misses on revenue
May 10Eagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphoma
Apr 30Eagle Pharmaceuticals (NASDAQ:EGRX) Could Easily Take On More Debt
Apr 15Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 55% Above Its Share Price
Mar 25Financial Position Analysis
Short Term Liabilities: EGRX's short term assets ($187.3M) exceed its short term liabilities ($86.6M).
Long Term Liabilities: EGRX's short term assets ($187.3M) exceed its long term liabilities ($66.2M).
Debt to Equity History and Analysis
Debt Level: EGRX's net debt to equity ratio (21.8%) is considered satisfactory.
Reducing Debt: EGRX's debt to equity ratio has increased from 25.2% to 27.8% over the past 5 years.
Debt Coverage: EGRX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: EGRX's interest payments on its debt are well covered by EBIT (7.2x coverage).